GlassScriptPhysician profile
Elsa Bucio
NPI 1053940882
$648.37
in general payments reported to CMS, 2019-2025
17 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.47 · 2023: $64.85 · 2024: $167 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $602 · Long Term Medical Supply Or Device Loan: $25.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.85 |
| Long Term Medical Supply Or Device Loan | $25.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $101.98 | 2024-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Neurocrine Biosciences, INC. | $70.74 | 2022-2025 | |
| Novo Nordisk INC | $64.52 | 2023-2025 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.09 | 2025 | Caplyta |
| Lilly USA, LLC | $46.83 | 2023-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $45.25 | 2024 | |
| Ani Pharmaceuticals, INC. | $44.71 | 2025 | Purified Cortrophin Gel |
| Gilead Sciences, INC. | $42.15 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $30.43 | 2025 | Rexulti |
| Alkermes, INC. | $25.75 | 2024 | Aristada, Lybalvi |
| Baxter Healthcare | $25.05 | 2023 | Hillrom - Cp 150 Resting Electrocardiograph |
| Verona Pharma, INC. | $24.56 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $20.75 | 2025 | |
| Lundbeck LLC | $17.46 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $13.86 | 2024 | Glassia |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.65 | 2023 | Pneumovax 23, Vaxneuvance, M-M-R II |
| Vanda Pharmaceuticals INC. | $13.59 | 2025 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elsa Bucio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.